eral years MRSA has caused an increasing number of community-onset infections [2] . MRSA is resistant to all b-lactam antibiotics and can cause a variety of infections, from cellulitis to necrotizing pneumonia [1] .
In studies focused on various American Indian and Alaska Native (AI/AN) populations, MRSA prevalence has been reported to be high. In one rural American Indian hospital, ∼55% of S. aureus isolates were found to be methicillin resistant [3] , and some Indian Health Service (IHS) clinics have reported methicillin resistance in 160% of S. aureus isolates [4] . Although the prevalence of MRSA infection in the AI/AN population has been studied in localized communities or regions throughout the country, to our knowledge, no studies have looked at MRSA-associated hospitalization rates in this population nationally.
In this study, we describe the occurrence of MRSA-associated hospitalizations among AI/ANs within the IHS health care system. The IHS is the agency within the Department of Health and Human Services that is responsible for providing health care to eligible AI/ANs. Approximately 1.6 million AI/ANs are eligible for IHS-funded medical care [5] .
METHODS
Hospital discharge records for AI/ANs were analyzed using the IHS National Patient Information Reporting System (NPIRS) for calendar years 1996-2005, with more detailed analysis for a 3-year baseline period (1996) (1997) (1998) , period 1) and the most recent 3-year period for which data were available (2003) (2004) (2005) , period 2). The NPIRS contains hospital discharge records from IHS and tribally operated health care facilities as well as from community hospitals and clinics that have contracted with the IHS or tribes to provide health care services to eligible AI/ANs [6, 7] .
MRSA-associated and methicillin-susceptible S. aureus (MSSA)-associated hospitalization rates were identified using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) [8] . An MRSA-associated hospitalization was defined as a hospitalization with a discharge diagnosis containing the code V09.0 (infection with microorganisms resistant to penicillins) and у1 of the following codes: 038.11 (S. aureus septicemia), 482.41 (S. aureus pneumonia), or 041.11 (S. aureus infection unspecified site). An MSSA-associated hospitalization was defined by a diagnosis of one of these 3 S. aureus-specific codes (038.11, 482.41, or 041.11) but without the V09.0 code. Hospitalizations with MRSA or MSSA listed as one of 15 discharge diagnoses were included. The unit of analysis in this study is a hospitalization.
The annual and the average annual hospitalization rates were expressed as the number of hospitalizations per 100,000 AI/ ANs. Annual population denominators were obtained by adjusting the 2005 fiscal year IHS population by the estimated annual proportional change in the number of eligible AI/ANs [7] . The user population was defined as all AI/ANs who received IHS-funded health care service at least once during the previous 3 years, which represents ∼81% of the 1.6 million eligible AI/ ANs [7] . Hospitalization rates for 1996-2005 and for comparison periods 1 and 2 were examined by sex, age group, and IHS region: East (Maine, New York, Massachusetts, Connecticut, Rhode Island, Pennsylvania, North Carolina, South Carolina, Florida, Alabama, and Louisiana); Northern Plains (Montana, Wyoming, North Dakota, South Dakota, Nebraska, Iowa, Minnesota, Wisconsin, Michigan, and Indiana); Southern Plains (Oklahoma and Kansas); Southwest (Arizona, New Mexico, Colorado, Utah, and Nevada); and Alaska (Alaska). The IHS California region (California) and Portland region (Washington, Oregon, and Idaho) were excluded from this study because neither had any IHS or tribally operated hospitals [5, 9] . In addition, the California region does not report inpatient diagnoses for contract health services, and Portland has limited contract health service funds for inpatient care [5, 9] . The California and Portland regions accounted for approximately 5% and 7% of the IHS user population, respectively [5] . Comparison of rates by sex, age group, and region was performed using Poisson regression analysis. Comparisons of rates across all study years were tested for a linear trend by means of a x 2 test for trend.
For period 2, rate comparisons between sexes, age groups, and regions were performed using risk ratios (RRs) with 95% confidence intervals (CIs). During this period, the following clinical diagnoses listed with an MRSA or MSSA diagnosis on the hospital discharge record were examined: skin and softtissue infection (SSTI) (682.0-682. 9 stay by MRSA-and MSSA-associated hospitalization was examined using the Wilcoxon rank-sum test. Hospital discharge data for the general United States population were also analyzed using the Nationwide Inpatient Sample for period 2. The Nationwide Inpatient Sample is the largest all-payer inpatient care database in the United States [10] . It is produced by the Healthcare Cost and Utilization Project, which is sponsored by the Agency for Healthcare Research and Quality in partnership with public and private statewide data organizations [10, 11] . The Nationwide Inpatient Sample is designed to approximate a 20% sample of US community hospitals. Hospitals in the sampling frame for 2003-2005 include short-term, nonfederal, general and specialty hospitals in 37 states; IHS-funded health care facilities are not included in the Nationwide Inpatient Sample. National hospitalization estimates are calculated using discharge weights developed by the Healthcare Cost and Utilization Project [10] [11] [12] .
For the general US population, hospitalizations with MRSA or MSSA listed as one of the top 15 discharge diagnoses were selected. The annual and the average annual hospitalization rates were expressed per 100,000 persons. Hospitalization rates were calculated by using the weighted number of hospitalizations and the census population for each year from the National Center for Health Statistics [13] . Standard errors for the US estimates were calculated using SUDAAN software (RTI International) to account for the sampling design and were used to calculate 95% CIs for the rates [14] . Age-adjusted and agespecific MRSA-associated hospitalization rates are reported for the comparison between IHS and general US populations for period 2. Age-adjusted hospitalization rates were calculated for AI/ANs and for the general US population by use of the study age groups and the Census 2000 projected US population, by the direct method of calculation [15] .
RESULTS
The MRSA-associated hospitalization rate increased steadily from 1996 to 2005, with an increase from 1.6 to 71.4 hospitalizations per 100,000 persons ( ). The MSSA-associated P ! .01 rate increased from 44.5 to 67.2 hospitalizations per 100,000 persons ( ) ( figure 1) .
The average annual MRSA-associated hospitalization rate among AI/ANs increased from 4.6 to 50.6 hospitalizations per 100,000 persons (RR, 11.0; 95% CI, 9.3-13.1), and MSSAassociated hospitalization rates increased from 49.3 to 60.5 hospitalizations per 100,000 persons (RR, 1.2; 95% CI, 1.2-1.3), between periods (table 1) . By 2005, MRSA accounted for the majority (52%) of all S. aureus-associated hospitalizations (figure 1) .
From period 1 to 2, MRSA-associated hospitalization rates In period 2, the median age of AI/ANs with MRSA-associated hospitalization was 42 years; the median length of hospital stay was 6 days. There was no difference between the overall median length of hospital stay for MRSA-associated hospitalizations and that for MSSA-associated hospitalizations or between the length of hospital stay for MRSA-and for MSSA-associated hospitalizations that were associated with diagnoses of S. aureus sepsis, bacteremia, bone infection, or S. aureus pneumonia.
Of 1838 MRSA-associated diagnoses in period 2, SSTI was associated with 1089 (59%), diabetes with 684 (37%), and bone infection with 328 (18%). Urinary tract infection (148 cases), S. aureus sepsis (119 cases), postoperative infection (99 cases), S. aureus pneumonia (73 cases), infection attributable to an implanted device (74 cases), and bacteremia (80 cases) were each associated with р8% of diagnoses (figure 2). There was a significant increase in the proportion of MRSA-associated SSTI between periods 1 and 2 (from 48% In 2003-2005, the age-adjusted MRSA-associated hospitalization rate among AI/ANs who used IHS health care was 58.8 hospitalizations per 100,000 persons, compared with 84.7 hospitalizations per 100,000 persons (95% CI, 82.8-86.6 hospitalizations per 100,000 persons) in the general US population. Age-specific rates appear similar for persons !65 years of age. MRSA-associated hospitalization rates in persons aged 65-84 years were 95.9 hospitalizations per 100,000 persons for the AI/ AN population and 263.3 hospitalizations per 100,000 persons (95% CI, 252.9-273.8 hospitalizations per 100,000 persons) for the general US population. Rates for persons aged у85 years were 134.1 hospitalizations per 100,000 persons for the IHS and 540.4 hospitalizations per 100,000 persons (95% CI, 514.9-565.9 hospitalizations per 100,000 persons) for the general US population (figure 4). The age-adjusted MRSA-associated hospitalization rate for the IHS Alaska region (116.0 hospitalizations per 100,000 persons) was higher than that for the general US population; the rates for all other regions were lower.
DISCUSSION
This study sought to determine the occurrence of MRSA-associated hospitalization among AI/ANs within the IHS health care system. We analyzed hospitalizations that are representative of the IHS population and found that MRSA-associated hospitalization rates have increased significantly. Rates have increased most notably in young children and in persons у65 years of age, with SSTI accounting for the greatest proportion of associated diagnoses.
The trends in MRSA-associated hospitalization rates seen in our study are consistent with national studies. A study by the Healthcare Cost and Utilization Project used the Nationwide Inpatient Sample to determine the rate of MRSA-associated hospitalization nationally from 1993 through 2005 [16] . They defined an MRSA hospitalization by the ICD-9-CM code for infection with microorganisms resistant to penicillins (V09.0) without an S. aureus-specific code, which made their definition less specific than the case definition used in our study. The authors found the MRSA-associated hospitalization rate increased nearly 10-fold during 1995-2005 [16] ; this rate is substantially higher than that seen in our study. However, given the less specific definition that was used in the Healthcare Cost and Utilization Project study (the V09.0 code can be used for any microorganism resistant to penicillins, such as penicillin-resistant Streptococcus), a higher estimate is expected in their study. An additional study, conducted by Klein et al [17] , examined MRSArelated hospitalizations by means of ICD-9-CM codes for S. aureus, with extrapolation of the proportion of isolates with methicillin resistance by means of laboratory susceptibility results from a nationally representative electronic depot of susceptibility results. In 2005, they estimated the rate of MRSArelated hospital discharges to be ∼8 MRSA-related hospital discharges per 1,000 discharges [17] . In our study, we reported MRSA-associated hospitalization rates by IHS-user population rather than by hospital discharge; the 2005 IHS MRSA-related hospital discharge rate (number of MRSA-related hospitalizations per hospital discharge) was ∼12 MRSA-related hospital- izations per 1,000 discharges, similar to the Klein et al study. Also consistent with national studies, males in our study had elevated rates of MRSA-associated hospitalization, compared with rates for females [16, 18] .
The Alaska and Southwest IHS regions had the highest MRSA-associated hospitalization rates. This follows a regional pattern of infectious disease hospitalization rates similar to the pattern in other studies that used the NPIRS dataset; AI/ANs in the Alaska and Southwest regions have been shown to have the highest rate of overall infectious disease hospitalization among AI/ANs in all IHS regions [19, 20] . Factors that may play a role in this disparity include a lack of water and a lack of sanitation services in these areas [21] .
There was little difference in MRSA-associated hospitalization rates between the IHS and general US populations for persons !65 years of age. Rates in age groups 65-84 and у85 years were ∼3-4 times higher nationally. However, hospitalization rates for the IHS and the general US populations were derived using different methodologies and therefore could not be compared statistically. A possible explanation for this disparity is that AI/ANs who reach age 65 are eligible for Medicare; therefore, they have more choices for medical care, such as care in noncontracted health care facilities that accept Medicare. This may account for some of the difference, because NPIRS does not include information on hospitalizations outside of IHS, tribal, and IHS contract facilities. Further investigation of this potential source of bias in NPIRS is necessary.
Consistent with national studies, the majority of MRSA-associated diagnoses in our study were SSTIs (59%) [16, 17] . We found that diagnosis of SSTI was more often associated with MRSA (59%) than with MSSA (45%) and that the proportion of MRSA-associated SSTI increased throughout the study period. Clinicians should have a high index of suspicion for MRSA infection when encountering patients with SSTI and adjust empirical therapy as appropriate.
Our study has a few limitations. First, the V09.0 code may be given a low discharge-diagnosis ranking order; by including only the top 15 discharge diagnoses in our analysis, we may have underestimated the number of MRSA-associated hospitalizations. However, у94% of hospitalizations in our study had !15 discharge diagnoses in both comparison periods. Second, the accuracy of ICD-9-CM coding is dependent on the experience of the coder. Although validation of the NPIRS dataset has shown high concordance with electronic medical records review (unpublished data, Arctic Investigations Program), our case definition requires 2 ICD-9-CM codes, which may make accurate coding more difficult. Third, because we analyzed hospital discharge data, we are unable to differentiate between hospitalization attributed to health care-associated MRSA infection and hospitalization attributed to communityacquired MRSA infection. Also, our study may not be representative of AI/ANs in the California and Portland regions or AI/ANs who do not use IHS health care. Last, we cannot account for hospital readmission(s) for an episode, and therefore each hospitalization does not necessarily represent an incident case.
MRSA-associated hospitalization increased significantly among AI/ANs who used the IHS health care system from 1996 to 2005, with MRSA now the causative organism of the largest proportion of S. aureus-associated hospitalizations. Increasing methicillin resistance is concerning for several reasons. MRSA is associated with significant mortality [18] and substantially increased medical costs [22, 23] , compared with its methicillin-sensitive counterpart. An increasing rate of MRSA-associated hospitalization will likely strain the limited IHS resources. Given this increase, clinicians should have a high index of suspicion for MRSA infection, especially in AI/AN patients who have SSTI, are у65 years of age, or reside in the Alaska and Southwest regions, and should adjust presumptive antibiotic therapy accordingly. Particular attention should be paid to the Alaska region, where rates of MRSA-associated hospitalization exceed national rates. Additional studies are needed to determine the proportion of hospitalizations attributable to community-acquired MRSA infection versus hospital-acquired MRSA infection as well as the rate of MRSA-associated mortality and other adverse events.
